<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008968</url>
  </required_header>
  <id_info>
    <org_study_id>Allo2013</org_study_id>
    <nct_id>NCT02008968</nct_id>
  </id_info>
  <brief_title>Effect of Allopurinol Treatment on Insulin Resistance</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medeniyet University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medeniyet University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies showed that hyperuricemia is an independent risk factor for development of
      diabetes mellitus. However none of the previous studies have investigated the effect of
      lowering serum uric acid levels on insulin resistance of which is also named as prediabetes.
      With this background in mind, we aimed to test the effect of lowering serum uric acid level
      with allopurinol on insulin resistance.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in insulin resistance (HOMA-IR)</measure>
    <time_frame>baseline and 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Prediabetes</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Uric acid ≥7 mg/dL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive allopurinol treatment. 50 subjects will be recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uric acid ≥6 and &lt;7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will not receive allopurinol. 50 subjects will be recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normouricemic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm is healthy controls. 30 subjects will be recruited.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allopurinol 300 mg./day</intervention_name>
    <arm_group_label>Uric acid ≥7 mg/dL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>Uric acid ≥6 and &lt;7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normouricemic</intervention_name>
    <arm_group_label>Normouricemic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 30

          -  Serum uric acid level ≥7mg/dL

          -  Glomerular filtration rate ≥60 ml/min

        Exclusion Criteria:

          -  presence of Diabetes Mellitus

          -  history of gout

          -  history of allopurinol use

          -  body mass index ≥35 kg/m2

          -  proteinuria ≥ 1gr/ day

          -  presence of autoimmune disease

          -  rheumatology associated disease

          -  presence of hypothyroidism or hyperthyroidism

          -  presence of diseases which may cause chronic inflammation or microalbuminuria (e.g.
             malignancy, chronic liver disease, hypertension, chronic lung disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Bakan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul Medeniyet University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mehmet Kanbay, Associate Professor</last_name>
    <phone>+902165709294</phone>
    <email>drkanbay@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istanbul Medeniyet University Goztepe Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Marmara</state>
        <zip>34353</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Kanbay, Associate Professor</last_name>
      <phone>+902165709294</phone>
      <email>drkanbay@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mehmet Kanbay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Medeniyet University</investigator_affiliation>
    <investigator_full_name>Mehmet Kanbay</investigator_full_name>
    <investigator_title>Associate Professor Doctor Mehmet Kanbay</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

